With the expiry of patents for the blockbuster molecules looming large, the camps of big pharma giants are in disarray. The brain-storming strategies and policies pertaining to evergreening of these patents may be seen in the days to come. Some of the big names in the game include the likes of Pfizer Inc., Merck & […]
In Apotex v. Pfizer (Sup. Ct. 05-1006), the Supreme Court said that it will not hear a case brought by generic pharmaceutical company Apotex that was trying to have Pfizer’s Zoloft patent invalidated. Zoloft (sertraline hydrochloride) is a selective serotonin reuptake inhibitor (SSRI) used to treat depression. Earlier, Pfizer sent Apotex an unconditional covenant not […]
Patents Drive the Economy A Special Report in the Toledo Blade newspaper points out that Ohio’s economy is closely tied to innovation. Manufacturing job loss doesn’t explain why the economy is lagging in certain states, like Ohio. A study by the Cleveland Federal Reserve Bank concluded that patents per-capita were the source of Ohio’s wealth. […]
The Supreme Court heard oral arguments in a case asking whether companies can sue to invalidate another’s patent even when they don’t face an infringement suit, a case that may affect thousands of drug and biotechnology inventions. The case, MedImmune, Inc. v. Genentech, Inc. et al. (No. 05-608), looks at whether a company must stop […]
The U.S. Patent and Trademark Office (USPTO) announced it will re-examine patents covering embryonic stem cell discoveries made by University of Wisconsin researchers. The patents, US Pat. Nos. 5,843,780, 6,200,806, and 7,029,913, cover all embryonic stem cell research in the U.S. The USPTO could revoke, modify or leave intact the patents but any such action […]
Welcome to the Autumnal Edition of Blawg Review, hosted this week by the Patent Baristas. We’re always glad to have people over to visit so grab a piping hot spiced latte and we’ll see what’s been going on around the blogosphere. Here in Cincinnati, OH, autumn is by far the best season with a drop […]
Served Up Daily
Editor-in-Chief Barista Stephen Jenei is a patent attorney and Owner of Jenei LLC. When not serving up patent chat over a steaming cup of java, he's handling a diverse intellectual property practice in the biotechnology, pharmaceutical and chemical fields. More info @ Jenei LLC
